Is ABS-301 at ABCSI our drug? It’s not disclosed
Post# of 148126
Watching the presentation now interesting.
“Stegmann also explained how Absci's reverse immunology technology elucidated a potentially novel mechanism of tumor immune evasion in conjunction with the development of ABS-301, which has broad first-in-class potential in immuno-oncology. Stegmann said that several other undisclosed assets are in the target evaluation stage. Find a recording of his full presentation here.”